A  ||| S:0 E:2 ||| DT
menthol-based  ||| S:2 E:16 ||| JJ
solid  ||| S:16 E:22 ||| JJ
dispersion  ||| S:22 E:33 ||| JJ
technique  ||| S:33 E:43 ||| NN
for  ||| S:43 E:47 ||| IN
enhanced  ||| S:47 E:56 ||| JJ
solubility  ||| S:56 E:67 ||| NN
and  ||| S:67 E:71 ||| CC
dissolution  ||| S:71 E:83 ||| NN
of  ||| S:83 E:86 ||| IN
sulfamethoxazole  ||| S:86 E:103 ||| NN
from  ||| S:103 E:108 ||| IN
an  ||| S:108 E:111 ||| DT
oral  ||| S:111 E:116 ||| JJ
tablet  ||| S:116 E:123 ||| NNS
matrix  ||| S:123 E:130 ||| VBP
A  ||| S:130 E:132 ||| DT
menthol-based  ||| S:132 E:146 ||| JJ
solid  ||| S:146 E:152 ||| JJ
dispersion  ||| S:152 E:163 ||| NN
was  ||| S:163 E:167 ||| VBD
designed  ||| S:167 E:176 ||| VBN
to  ||| S:176 E:179 ||| TO
improve  ||| S:179 E:187 ||| VB
the  ||| S:187 E:191 ||| DT
intrinsic  ||| S:191 E:201 ||| JJ
solubility  ||| S:201 E:212 ||| NN
of  ||| S:212 E:215 ||| IN
the  ||| S:215 E:219 ||| DT
poorly  ||| S:219 E:226 ||| RB
soluble  ||| S:226 E:234 ||| JJ
sulfamethoxazole-  ||| S:234 E:252 ||| JJ
a  ||| S:252 E:254 ||| DT
class  ||| S:254 E:260 ||| NN
II  ||| S:260 E:263 ||| NNP
drug  ||| S:263 E:268 ||| NN
molecule  ||| S:268 E:277 ||| NN
of  ||| S:277 E:280 ||| IN
Biopharmaceutics  ||| S:280 E:297 ||| NNP
Classification  ||| S:297 E:312 ||| NNP
System  ||| S:312 E:319 ||| NNP
( ||| S:319 E:320 ||| -LRB-
BCS ||| S:320 E:323 ||| NNP
)  ||| S:323 E:325 ||| -RRB-
displaying  ||| S:325 E:336 ||| VBG
widespread  ||| S:336 E:347 ||| JJ
antibacterial  ||| S:347 E:361 ||| JJ
activity ||| S:361 E:369 ||| NN
.  ||| S:369 E:371 ||| .
Solid  ||| S:371 E:377 ||| JJ
dispersions  ||| S:377 E:389 ||| NN
of  ||| S:389 E:392 ||| IN
menthol  ||| S:392 E:400 ||| NN
and  ||| S:400 E:404 ||| CC
sulfamethoxazole  ||| S:404 E:421 ||| NNS
were  ||| S:421 E:426 ||| VBD
compressed  ||| S:426 E:437 ||| VBN
with  ||| S:437 E:442 ||| IN
hydroxypropyl  ||| S:442 E:456 ||| JJ
methylcellulose  ||| S:456 E:472 ||| NNS
( ||| S:472 E:473 ||| -LRB-
HPMC ||| S:473 E:477 ||| NNP
)  ||| S:477 E:479 ||| -RRB-
into  ||| S:479 E:484 ||| IN
suitable  ||| S:484 E:493 ||| JJ
sulfamethoxazole-loaded  ||| S:493 E:517 ||| JJ
matrix  ||| S:517 E:524 ||| JJ
tablets  ||| S:524 E:532 ||| NNS
for  ||| S:532 E:536 ||| IN
oral  ||| S:536 E:541 ||| JJ
drug  ||| S:541 E:546 ||| NN
delivery ||| S:546 E:554 ||| NN
.  ||| S:554 E:556 ||| .
The  ||| S:556 E:560 ||| DT
sulfamethoxazole-loaded  ||| S:560 E:584 ||| JJ
solid  ||| S:584 E:590 ||| JJ
dispersions  ||| S:590 E:602 ||| NN
and  ||| S:602 E:606 ||| CC
compressed  ||| S:606 E:617 ||| JJ
tablets  ||| S:617 E:625 ||| NNS
were  ||| S:625 E:630 ||| VBD
characterized  ||| S:630 E:644 ||| VBN
for  ||| S:644 E:648 ||| IN
their  ||| S:648 E:654 ||| PRP$
physicochemical  ||| S:654 E:670 ||| NN
and  ||| S:670 E:674 ||| CC
physicomechanical  ||| S:674 E:692 ||| JJ
properties  ||| S:692 E:703 ||| NNS
such  ||| S:703 E:708 ||| JJ
as  ||| S:708 E:711 ||| IN
changes  ||| S:711 E:719 ||| NNS
in  ||| S:719 E:722 ||| IN
crystallinity ||| S:722 E:735 ||| NN
,  ||| S:735 E:737 ||| ,
melting  ||| S:737 E:745 ||| VBG
point ||| S:745 E:750 ||| NN
,  ||| S:750 E:752 ||| ,
molecular  ||| S:752 E:762 ||| JJ
transitions ||| S:762 E:773 ||| NN
,  ||| S:773 E:775 ||| ,
and  ||| S:775 E:779 ||| CC
textural  ||| S:779 E:788 ||| JJ
analysis  ||| S:788 E:797 ||| NN
for  ||| S:797 E:801 ||| IN
critical  ||| S:801 E:810 ||| JJ
analysis  ||| S:810 E:819 ||| NN
of  ||| S:819 E:822 ||| IN
their  ||| S:822 E:828 ||| PRP$
effects  ||| S:828 E:836 ||| NNS
on  ||| S:836 E:839 ||| IN
the  ||| S:839 E:843 ||| DT
solubility  ||| S:843 E:854 ||| NN
and  ||| S:854 E:858 ||| CC
dissolution  ||| S:858 E:870 ||| NN
of  ||| S:870 E:873 ||| IN
sulfamethoxazole ||| S:873 E:889 ||| NN
.  ||| S:889 E:891 ||| .
The  ||| S:891 E:895 ||| DT
formulations  ||| S:895 E:908 ||| NN
were  ||| S:908 E:913 ||| VBD
further  ||| S:913 E:921 ||| RB
evaluated  ||| S:921 E:931 ||| VBN
for  ||| S:931 E:935 ||| IN
swelling ||| S:935 E:943 ||| VBG
,  ||| S:943 E:945 ||| ,
degradation ||| S:945 E:956 ||| NN
,  ||| S:956 E:958 ||| ,
solubility ||| S:958 E:968 ||| NN
,  ||| S:968 E:970 ||| ,
and  ||| S:970 E:974 ||| CC
in  ||| S:974 E:977 ||| IN
vitro  ||| S:977 E:983 ||| JJ
drug  ||| S:983 E:988 ||| NN
release  ||| S:988 E:996 ||| NN
behavior ||| S:996 E:1004 ||| NN
.  ||| S:1004 E:1006 ||| .
In  ||| S:1006 E:1009 ||| IN
vitro  ||| S:1009 E:1015 ||| JJ
drug  ||| S:1015 E:1020 ||| NN
release  ||| S:1020 E:1028 ||| NN
from  ||| S:1028 E:1033 ||| IN
the  ||| S:1033 E:1037 ||| DT
sulfamethoxazole-loaded  ||| S:1037 E:1061 ||| JJ
matrix  ||| S:1061 E:1068 ||| JJ
tablets  ||| S:1068 E:1076 ||| NNS
displayed  ||| S:1076 E:1086 ||| VBD
a  ||| S:1086 E:1088 ||| DT
minimum  ||| S:1088 E:1096 ||| NN
and  ||| S:1096 E:1100 ||| CC
maximum  ||| S:1100 E:1108 ||| JJ
fractional  ||| S:1108 E:1119 ||| JJ
release  ||| S:1119 E:1127 ||| NN
of  ||| S:1127 E:1130 ||| IN
0.714  ||| S:1130 E:1136 ||| NNP
and  ||| S:1136 E:1140 ||| CC
0.970 ||| S:1140 E:1145 ||| NNP
,  ||| S:1145 E:1147 ||| ,
respectively ||| S:1147 E:1159 ||| RB
.  ||| S:1159 E:1161 ||| .
The  ||| S:1161 E:1165 ||| DT
tablets  ||| S:1165 E:1173 ||| NNS
further  ||| S:1173 E:1181 ||| RB
displayed  ||| S:1181 E:1191 ||| VBN
different  ||| S:1191 E:1201 ||| JJ
release  ||| S:1201 E:1209 ||| NN
rate  ||| S:1209 E:1214 ||| NN
profiles  ||| S:1214 E:1223 ||| NNS
over  ||| S:1223 E:1228 ||| IN
the  ||| S:1228 E:1232 ||| DT
study  ||| S:1232 E:1238 ||| NN
periods  ||| S:1238 E:1246 ||| NNS
of  ||| S:1246 E:1249 ||| IN
12 ||| S:1249 E:1251 ||| CD
,  ||| S:1251 E:1253 ||| ,
16 ||| S:1253 E:1255 ||| CD
,  ||| S:1255 E:1257 ||| ,
48 ||| S:1257 E:1259 ||| CD
,  ||| S:1259 E:1261 ||| ,
and  ||| S:1261 E:1265 ||| CC
56Â h  ||| S:1265 E:1270 ||| NNP
which  ||| S:1270 E:1276 ||| WDT
were  ||| S:1276 E:1281 ||| VBD
attributed  ||| S:1281 E:1292 ||| VBN
to  ||| S:1292 E:1295 ||| TO
the  ||| S:1295 E:1299 ||| DT
varying  ||| S:1299 E:1307 ||| JJ
concentrations  ||| S:1307 E:1322 ||| NNS
of  ||| S:1322 E:1325 ||| IN
menthol  ||| S:1325 E:1333 ||| NN
within  ||| S:1333 E:1340 ||| IN
each  ||| S:1340 E:1345 ||| DT
formulation ||| S:1345 E:1356 ||| NN
.  ||| S:1356 E:1358 ||| .
Menthol  ||| S:1358 E:1366 ||| NNP
was  ||| S:1366 E:1370 ||| VBD
determined  ||| S:1370 E:1381 ||| VBN
as  ||| S:1381 E:1384 ||| IN
a  ||| S:1384 E:1386 ||| DT
suitable  ||| S:1386 E:1395 ||| JJ
hydrophilic  ||| S:1395 E:1407 ||| JJ
carrier  ||| S:1407 E:1415 ||| NN
for  ||| S:1415 E:1419 ||| IN
sulfamethoxazole  ||| S:1419 E:1436 ||| NN
since  ||| S:1436 E:1442 ||| IN
it  ||| S:1442 E:1445 ||| PRP
functioned  ||| S:1445 E:1456 ||| VBD
as  ||| S:1456 E:1459 ||| IN
a  ||| S:1459 E:1461 ||| DT
solubilizing  ||| S:1461 E:1474 ||| NN
and  ||| S:1474 E:1478 ||| CC
release-retarding  ||| S:1478 E:1496 ||| JJ
agent  ||| S:1496 E:1502 ||| NN
for  ||| S:1502 E:1506 ||| IN
improving  ||| S:1506 E:1516 ||| VBG
the  ||| S:1516 E:1520 ||| DT
solubility  ||| S:1520 E:1531 ||| NN
and  ||| S:1531 E:1535 ||| CC
dissolution  ||| S:1535 E:1547 ||| NN
of  ||| S:1547 E:1550 ||| IN
sulfamethoxazole  ||| S:1550 E:1567 ||| NN
as  ||| S:1567 E:1570 ||| IN
well  ||| S:1570 E:1575 ||| RB
as  ||| S:1575 E:1578 ||| IN
controlling  ||| S:1578 E:1590 ||| VBG
the  ||| S:1590 E:1594 ||| DT
rate  ||| S:1594 E:1599 ||| NN
at  ||| S:1599 E:1602 ||| IN
which  ||| S:1602 E:1608 ||| WDT
it  ||| S:1608 E:1611 ||| PRP
was  ||| S:1611 E:1615 ||| VBD
released ||| S:1615 E:1623 ||| VBN
.  ||| S:1623 E:1625 ||| .
